Nivolumab-Based Treatment Yields Long-Term Survival in Resectable NSCLC
Perioperative nivolumab (Opdivo)-based treatment demonstrated long‑term survival among patients with resectable stage IIA to IIIA non‑small cell lung cancer (NSCLC), especially among those with a pathological complete response (pCR).
Perioperative nivolumab treatment demonstrated long-term survival among patients with resectable stage IIA‑IIIA non‑small cell lung cancer (NSCLC), especially among those with a pathological complete response, according to a phase 2 trial (NCT04015778). After a median follow‑up of 50.5 months, the event‑free survival (EFS) and overall survival (OS) rates for the intent‑to‑treat population were 57.2 % and 72.1 %, respectively. In patients with a pathological complete response (pCR), 4‑year EFS was 79.7 % and OS was 94.1 %. The study also identified that ≥13 cycles of adjuvant nivolumab correlated with improved 3‑year EFS (79 % vs 60 %) and suggested that LAMPAD‑low‑risk patients may be candidates for treatment de‑escalation.
This finding supports the use of perioperative nivolumab as a standard of care for early‑stage NSCLC, potentially reducing the need for extensive adjuvant therapy in patients identified as low risk.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT